AKUOS (nea, ra) genética - auditiva, hearing loss ( creo que la única), veo que están preparando también algo genético para pérdida cabello presentación january 2021
ipo hace varios meses a 17, hoy un poc por debajo, maket cap casi 578M, cash x2years
Recent Business Highlights
Appointed Alan Smith, Ph.D., as chief technology officer – In June 2020, Alan Smith, Ph.D., joined Akouos as chief technology officer. Dr. Smith brings over 30 years of experience in cellular therapeutics and previously served as executive vice president, technical operations at Bellicum Pharmaceuticals.
Strengthened board of directors with appointment of Saira Ramasastry – In June 2020, Saira Ramasastry joined the board of directors of Akouos. Ms. Ramasastry currently serves as managing partner of Life Sciences Advisory, a firm that she founded to provide strategic advice and business development solutions for life science companies.
Expanded the role of Arthur Tzianabos, Ph.D. to chairman of board of directors – In August 2020, Akouos announced the appointment of its board member Arthur Tzianabos to chairman of the board of directors.
Completed upsized Initial Public Offering – In June 2020, Akouos completed its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including the full exercise of the underwriter’s option to purchase additional shares. Gross proceeds from the IPO were $244.4 million and net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $223.8 million.
Presented two posters at the American Society of Gene & Cell Therapy 23rd Annual Meeting – In May 2020, Akouos presented two posters highlighting Akouos’s use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.
Second Quarter 2020 Financial Results
Cash Position – Cash and cash equivalents were $333.0 million as of June 30, 2020, as compared to $120.2 million as of March 31, 2020. Total cash, cash equivalents and marketable securities at June 30, 2020 includes total net proceeds of approximately $223.8 million from the company’s IPO in June 2020. Akouos expects the cash balance to fund operations for at least the next two years.
Research and Development (R&D) Expenses – R&D expenses were $9.9 million for the second quarter ended June 30, 2020, compared to $4.4 million for the same period in 2019. The increase was primarily due to contract manufacturing costs, the initiation of preclinical IND-enabling studies for AK-OTOF, and the growth in the number of R&D employees and their related activities, as well as the expense allocated to R&D related to Akouos’s leased facilities.
General and Administrative (G&A) Expenses – G&A expenses were $2.7 million for the second quarter ended June 30, 2020, compared to $0.7 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees and other administrative expenses, as well as the expense allocated to G&A related to Akouos’s leased facilities.
Net Loss – Net loss was $12.5 million, or $11.14 loss per share, for the second quarter ended June 30, 2020, compared to $2.0 million, or $3.42 loss per share, for the same period in 2019.
creo que voy a iniciar posición, si te interesa y la miras ya comentarás!
(RTTNews) - The lockup period of Akouos Inc. (AKUS) expires tomorrow, i.e. on Dec. 23.
he iniciado posición 16,7$ , como de costumbre, pequeña y una fracción de lo que estaría dispuesto a meter,
ojo, muy ilíquida parece, muy muy seca...
#126804
Re: Farmas USA
Justo, a partir de la fecha que volvió a caer. Por eso te preguntaba ya q suele ser así, cuando ya pueden vender los insiders. No la he mirado a fondo pero digamos que no la tengo en mi lista de favoritas genéticas , que son las q tienen mi prioridad a su precio justo
#126805
Re: Farmas USA
TEVA Que guarras hoy,,,, viendo pasar el tren,,, Pero por mi,,, que sigan subiendo,, :))
#126806
Re: Farmas USA
EXEL
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Por si alguien la llevara, aunque en el precio hoy no se ha notado mucho, igual le puede dar un giro a la caída que lleva del 61 fibo
Diario
#126807
Re: Farmas USA
AMRN
Ojo con la vela diaria y donde se produce, y posibles giros en MACD y Estocastico, con la sobrecompra en diario. Dejo el lio de gráfico, no quiero borrar ciertas cosas.
#126808
Re: Farmas USA
Que te dice la vela? Supones que subirá o bajará y perdon pero no estoy muy puesto!
